Clinical trial
An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes
NCT04270942 is registered in ClinicalTrials.gov with Provention Bio, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At-Risk Relatives Who Develop Type 1 Diabetes
- Lead sponsor
- Provention Bio, a Sanofi Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 26, 2020
- Completion date
- January 22, 2024
- Enrollment
- 6 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.